High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic review